Nephro-Urology Monthly

Published by: Kowsar

Efficacy of Tadalafil on Ureteral Stent Symptoms: A Randomized Controlled Trial

Alireza Farshi Haghro 1 , * , Sakineh Hajebrahimi 1 , ** , Abbas Jabbari 1 , Homayoun Sadeghi 2 and Hossein Babaei 3
Authors Information
1 Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran
3 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Corresponding Authors:
Article information
  • Nephro-Urology Monthly: 11 (1); e85523
  • Published Online: February 5, 2019
  • Article Type: Research Article
  • Received: October 19, 2018
  • Accepted: December 3, 2018
  • DOI: 10.5812/numonthly.85523

To Cite: Farshi Haghro A, Hajebrahimi S, Jabbari A, Sadeghi H, Babaei H. Efficacy of Tadalafil on Ureteral Stent Symptoms: A Randomized Controlled Trial, Nephro-Urol Mon. Online ahead of Print ; 11(1):e85523. doi: 10.5812/numonthly.85523.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Jeong H, Kwak C, Lee SE. Ureteric stenting after ureteroscopy for ureteric stones: A prospective randomized study assessing symptoms and complications. BJU Int. 2004;93(7):1032-4. discussion 1034-5. doi: 10.1111/j.1464-410X.2004.4776a.x. [PubMed: 15142158].
  • 2. Irani J, Siquier J, Pires C, Lefebvre O, Dore B, Aubert J. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int. 1999;84(3):276-9. doi: 10.1046/j.1464-410x.1999.00154.x. [PubMed: 10468721].
  • 3. Haleblian G, Kijvikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: A systematic review. J Urol. 2008;179(2):424-30. doi: 10.1016/j.juro.2007.09.026. [PubMed: 18076928].
  • 4. Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065-9. discussion 1069. doi: 10.1097/01.ju.0000048980.33855.90. [PubMed: 12576847].
  • 5. Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59(4):511-6. doi: 10.1016/S0090-4295(01)01644-2. [PubMed: 11927301].
  • 6. Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Heidari Nejad S, Esmaeili S. Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: A double-blind placebo-controlled randomized clinical trial. Urol Int. 2011;87(1):19-22. doi: 10.1159/000323855. [PubMed: 21597261].
  • 7. Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011;186(3):928-34. doi: 10.1016/j.juro.2011.04.061.
  • 8. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009;23(11):1913-7. doi: 10.1089/end.2009.0173. [PubMed: 19814699].
  • 9. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res. 2009;37(3):147-52. doi: 10.1007/s00240-009-0182-8. [PubMed: 19277623].
  • 10. Tehranchi A, Rezaei Y, Khalkhali HR, Rezaei M. Effects of terazosin and tolterodine on ureteral stent related symptoms: A double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2013;39(6):832-40. doi: 10.1590/s1677-5538.ibju.2013.06.09.
  • 11. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67(1):35-9. doi: 10.1016/j.urology.2005.07.038. [PubMed: 16413328].
  • 12. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. J Endourol. 2008;22(4):651-6. doi: 10.1089/end.2007.0257. [PubMed: 18338955].
  • 13. Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4). doi: 10.1002/14651858.CD003781.pub2.
  • 14. Patel B, Bavendam T, Badlani G. Use of antimuscarinics in the elderly. ScientificWorldJournal. 2009;9:459-65. doi: 10.1100/tsw.2009.55. [PubMed: 19526185]. [PubMed Central: PMC5823097].
  • 15. Speakman MJ. PDE5 inhibitors in the treatment of LUTS. Curr Pharm Des. 2009;15(30):3502-5. doi: 10.2174/138161209789207051. [PubMed: 19860696].
  • 16. Oger S, Behr-Roussel D, Gorny D, Lebret T, Validire P, Cathelineau X, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Brit J Pharm. 2010;160(5):1135-43. doi: 10.1111/j.1476-5381.2010.00748.x.
  • 17. Bittencourt JA, Tano T, Gajar SA, Resende AC, de Lemos Neto M, Damiao R, et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology. 2009;73(2):427-30. doi: 10.1016/j.urology.2008.06.060. [PubMed: 18774591].
  • 18. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, et al. The efficacy and safety of tadalafil: An update. BJU Int. 2004;93(9):1276-81. doi: 10.1111/j.1464-410X.2004.04819.x. [PubMed: 15180622].
  • 19. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280-8. doi: 10.1111/j.1365-2125.2005.02553.x. [PubMed: 16487221]. [PubMed Central: PMC1885023].
  • 20. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401-7. doi: 10.1016/j.juro.2006.11.037. [PubMed: 17382741].
  • 21. Jabbari A, Farshi A, Sadeghi Bazargani H, Hajebrahimi S. Validity and reliability of the ureteral stent symptoms questionnaire to Persian language. J Anal Res Clin Med. 2015;3(1):17-22. doi: 10.15171/jarcm.2015.003.
  • 22. Lim KT, Kim YT, Lee TY, Park SY. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol. 2011;52(7):485-8. doi: 10.4111/kju.2011.52.7.485. [PubMed: 21860770]. [PubMed Central: PMC3151637].
  • 23. Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41(3):247-52. doi: 10.1007/s00240-013-0554-y. [PubMed: 23515684].
  • 24. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol. 2009;55(1):38-48. doi: 10.1016/j.eururo.2008.08.062. [PubMed: 18783872].
  • 25. Madani AH, Afsharimoghaddam A, Roushani A, Farzan A, Asadollahzade A, Shakiba M. Evaluation of tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication. Int Braz J Urol. 2012;38(1):33-9. doi: 10.1590/S1677-55382012000100005. [PubMed: 22397784].
  • 26. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: A prospective, randomized, placebo controlled study. J Urol. 2009;181(1):170-6. doi: 10.1016/j.juro.2008.09.026. [PubMed: 19013590].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments